Top 10 HIV Clinical Developments of 2020
In this exclusive series of articles, David Alain Wohl, M.D., calls attention to 10 developments that have tremendous short-term implications for our day-to-day efforts to improve HIV prevention, treatment, patient care, and policy in the U.S., and analyzes each development with his trademark wit and clinical savvy.
LGBTQ Health and Well-Being: Where Is the U.S. Right Now?
Tonia Poteat, Ph.D., PA-C, M.P.H., and Marlon M. Bailey, Ph.D., dive into the important takeaways of a major new report on sexual and gender diverse populations in the U.S.
How Can We Manage Pain Better in Older Adults Living With HIV?
“Telling them now that ‘the government is saying I need to decrease your opioids. ... Sorry you’re going to suffer,’ was just not satisfying to me as a physician,” says Maile Young Karris, M.D.
HIV Incidence Is Lower in States With More Generous Low-Income Food Benefits
“The message that needs to be communicated to people in power, and it needs to be communicated loud and frequently, is, ‘Look. Here’s the actual human cost of not enacting these kinds of policies. Here’s the potential benefit,’” says Aaron Richterman, M.D., M.P.H.
Our Newest Posts
HIV in the Time of COVID-19
While we remain uncertain about the precise level of interaction (if any) between HIV and SARS-CoV-2 on a pathophysiological level, the pandemic’s disruption of HIV care is irrefutable.
HIV PrEP Is Finally About to Get Its Shot
PrEP for HIV is a pill. It has always been a pill. But it will not always be a pill, thanks to two major trials evaluating cabotegravir, an integrase inhibitor formulated for intramuscular injection, as PrEP.
PrEP and Prior Authorization: A Discriminatory Cheap Ploy
An important new analysis describes a key barrier to PrEP in the U.S., one that is almost sinister in its application predominantly in southern states.
Mortality Is Way Down Among People With HIV in the U.S.
A new report from the CDC highlights encouraging trends in death rates among people with HIV in the U.S., and is explicit in associating them with strong and concerted public health interventions.
What Drives Lower Life Expectancy for People With HIV in the U.S.?
Given the decline in mortality among people living with HIV in the U.S., it’s no surprise that the difference in life expectancy between those with and without the virus is shrinking. But the disparities that remain are striking.
Fostemsavir, at Last: A New Treatment Option for Extensive HIV Drug Resistance
Most people living with HIV will never need fostemsavir. But for those who do, the drug can be a life-saver—and that is pretty epic.
Refer your clients and patients to TheBody, TheBodyPro's sibling site for people living with or affected by HIV. TheBody delivers vital information, news, support, and personal perspectives on HIV and related issues.
